Literature DB >> 2121624

Longitudinal study of thyroid function in acutely ill elderly patients using a sensitive TSH assay-defer testing until recovery.

H L Bhakri1, R Fisher, A Khadri, D G MacMahon.   

Abstract

A prospective longitudinal study of thyroid function was conducted in 180 consecutive admissions to an acute geriatric unit. The rest strategy included assay of TSH and TRH testing when appropriate. On admission TSH was suppressed (less than 0.1 mU/l) in 17 patients (9.4%) and elevated (greater than 4.0 mU/l) in 8 (4.4%). Follow-up of these initial abnormalities showed resolution in almost all cases. Our findings suggest that acute illness may interfere with the hypothalamic-pituitary-thyroid axis, causing either temporary suppression or stimulation of TSH release. Although no new cases of thyroid disease were diagnosed, the prevalence of established dysfunction was 3.3% (2.7% hypothyroid; 0.6% hyperthyroid). To avoid misleading results, testing of thyroid dysfunction should be delayed until recovery from illness.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121624     DOI: 10.1159/000213189

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  3 in total

1.  Unmasking Hyperthyroidism in the Elderly: How to distinguish hyperthyroidism from conditions that mimic the symptoms.

Authors:  M Gordon; Y Isenberg; J Bain
Journal:  Can Fam Physician       Date:  1992-10       Impact factor: 3.275

2.  Impact of thyroid function screening in a large cohort of patients admitted to an emergency department.

Authors:  Irene Campi; Giovanni Battista Perego; Antonella Ravogli; Francesca Santafede; Federica Sileo; Antonella Dubini; Gianfranco Parati; Luca Persani; Laura Fugazzola
Journal:  Intern Emerg Med       Date:  2022-08-25       Impact factor: 5.472

Review 3.  To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence?

Authors:  Jan Calissendorff; Henrik Falhammar
Journal:  Medicina (Kaunas)       Date:  2020-01-19       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.